Table 4. Characteristics according to... | American Society of Hematology

Table 4.

Characteristics according to type of chronic GVHD

	De novo	Relapsing	Progressive	P
No. patients	17	30	16	—
Response (CR/PR), no. (%)	13 (76)	17 (57)	7 (44)	.07
More than 2 prior treatments, no. (%)*	3 (18)	13 (48)	7 (44)	.05
Platelet count below 100 000/mm³ at ECP, no. (%)†	5 (29)	8 (27)	11 (69)	.3
Scleroderma, no. (%)‡	11/14 (79)§	9/27 (33)	1/9 (11)	.002
Time from chronic GVHD to ECP, median (range)	512 (23-1537)	263 (1-1205)	90 (4-1351)	.02

	De novo	Relapsing	Progressive	P
No. patients	17	30	16	—
Response (CR/PR), no. (%)	13 (76)	17 (57)	7 (44)	.07
More than 2 prior treatments, no. (%)*	3 (18)	13 (48)	7 (44)	.05
Platelet count below 100 000/mm³ at ECP, no. (%)†	5 (29)	8 (27)	11 (69)	.3
Scleroderma, no. (%)‡	11/14 (79)§	9/27 (33)	1/9 (11)	.002
Time from chronic GVHD to ECP, median (range)	512 (23-1537)	263 (1-1205)	90 (4-1351)	.02

— indicates not applicable.

Including tacrolimus or cyclosporine.

100 000/mm³ is equal to 100 × 10⁹/L.

When skin was the only organ involved.

Eleven out of 14 patients with scleroderma.